FMP
Chinook Therapeutics, Inc.
KDNY
NASDAQ
Inactive Equity
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
40.39 USD
0.09 (0.223%)
About
ceo
Mr. Eric L. Dobmeier J.D.
sector
Healthcare
industry
Biotechnology
website
https://www.chinooktx.com
exchange
NASDAQ
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headq...
CIK
0001435049
ISIN
US00739L1017
CUSIP
16961L106
Address
400 Fairview Avenue North
Phone
206 485 7241
Country
US
Employee
214
IPO Date
Oct 6, 2020
Summary
CIK
0001435049
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
16961L106
ISIN
US00739L1017
Country
US
Price
40.39
Beta
0.67
Volume Avg.
2.04M
Market Cap
2.71B
Shares
-
52-Week
18.34-40.51
DCF
15.34
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-12.47
P/B
-
Website
https://www.chinooktx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest KDNY News
It looks like there's no news available.
